PROFIL EKONOMI PETERNAKAN SAPI PERAH DIWONOCOLO-SURABAYA

Berdasarkan dari hasi] analisis yang telah dilakukan, dapat ditarik kesimpulan bahwa usaha peternakan sapi perah di daerah Wonocolo, Surabaya menguntungka

Genetic characterization of H5N1 influenza viruses isolated from chickens in Indonesia in 2010

Since 2003, highly pathogenic H5N1 avian influenza viruses have caused outbreaks among poultry in Indonesia every year, producing the highest number of human victims worldwide. However, little is known about the H5N1 influenza viruses that have been circulating there in recent years. We therefore conducted surveillance studies and isolated eight H5N1 viruses from chickens. Phylogenic analysis of their hemagglutinin and neuraminidase genes revealed that all eight viruses belonged to clade 2.1.3. However, on the basis of nucleotide differences, these viruses could be divided into two groups. Other viruses genetically closely related to these two groups of viruses were all Indonesian isolates, suggesting that these new isolates have been evolving within Indonesia. Among these viruses, two distinct viruses circulated in the Kalimantan islands during the same season in 2010. Our data reveal the continued evolution of H5N1 viruses in Indonesia

Better Pandemic Influenza Preparedness through Adjuvant Technology Transfer: Challenges and Lessons Learned

Adequate global vaccine coverage during an influenza pandemic is essential to mitigate morbidity, mortality, and economic impact. Vaccine development and production needs to be sufficient to meet a vast global demand, requiring international cooperation and local vaccine production capacity, especially in resource-constrained countries. The use of adjuvants is one approach to augment the number of available vaccine doses and to overcome potential vaccine shortages. Appropriately selected adjuvant technologies can decrease the amount of vaccine antigen required per dose, may broaden or lengthen the conferred protection against disease, and may even allow protective single-dose vaccination. Here we describe a technology transfer collaboration between Switzerland and Indonesia that led to the establishment of a vaccine formulation platform in Surabaya which involved the transfer of equipment and expertise to enable research and development of adjuvanted vaccine formulations and delivery systems. This new Indonesian capability aims to facilitate local and regional access to know-how relating to adjuvanted vaccine formulations, thus promoting their application to local vaccine developers. In this review, we aim to share the "lessons learned" from this project to both support and inspire future scientific collaborations of a similar nature

Better Pandemic Influenza Preparedness through Adjuvant Technology Transfer: Challenges and Lessons Learned

Adequate global vaccine coverage during an influenza pandemic is essential to mitigate morbidity, mortality, and economic impact. Vaccine development and production needs to be sufficient to meet a vast global demand, requiring international cooperation and local vaccine production capacity, especially in resource-constrained countries. The use of adjuvants is one approach to augment the number of available vaccine doses and to overcome potential vaccine shortages. Appropriately selected adjuvant technologies can decrease the amount of vaccine antigen required per dose, may broaden or lengthen the conferred protection against disease, and may even allow protective single-dose vaccination. Here we describe a technology transfer collaboration between Switzerland and Indonesia that led to the establishment of a vaccine formulation platform in Surabaya which involved the transfer of equipment and expertise to enable research and development of adjuvanted vaccine formulations and delivery systems. This new Indonesian capability aims to facilitate local and regional access to know-how relating to adjuvanted vaccine formulations, thus promoting their application to local vaccine developers. In this review, we aim to share the “lessons learned” from this project to both support and inspire future scientific collaborations of a similar nature

Protection and profile of immune response against SARS-CoV-2 among the COVID-19 vaccinated and unvaccinated individuals

Coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was first reported in the city of Wuhan, China at the end of December 2019. In the case of SARS-CoV-2, antibody-mediated immunity and T cells are the most effective protection. This study aimed to analyze IFN-γ profile in people who were vaccinated and unvaccinated against COVID-19. This research was conducted at the Molecular Laboratory of the Professor Nidom Foundation (LM-PNF), Surabaya, Indonesia from February 2021 to March 2022 using 100 blood samples with details of 50 samples from people who had been vaccinated against COVID-19 and 50 samples from people who had unvaccinated against COVID-19. We divided into four: vaccination only, vaccination and had infected of COVID-19 or survivors, unvaccination only, and unvaccination but survivors. Furthermore, we used the ELISpot method to see the IFN-γ profile. The data analysed by using ANOVA. The results of this study showed that IFN-γ profile vary widely with the highest IFN-γ obtained in samples of people who are vaccinated and had infected of COVID-19 compared to other groups. In summary, we conclude that the cellular immune response (IFN-γ) profile in people who vaccinated and had infected of COVID-19 was better than unvaccinated

Interferon-Gamma profile of mice (Mus musculus L.) after complete SARS-CoV-2 vaccination

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (COVID-19) have afflicted millions of people in a worldwide pandemic. Several vaccines have been developed to prevent infection and illness. The success of preventing and controlling the COVID-19 by using an effective and efficient vaccine. This study aimed to find out the profile of interferon-gamma (IFN-γ) after COVID-19 vaccination. This study conducted at Animal Laboratory Professor Nidom Foundation (ABSL-3) from December 2021 to February 2022. The present study is an experimental study with a post test only control group design using 90 mice (Mus musculus L.). The test group consisted of mice injected subcutan with 0.1 mL PBS (P1), 0.1 mL adjuvant 1 (P2), 0.1 mL adjuvant 2 (P3), 0.1 mL VLPs SARS-CoV-2 10 μg (P4), 0.1 mL VLPs SARS-CoV-2 dose 50 μg (P5), 0.1 mL VLPs SARS-CoV-2 10 μg + adjuvant 1 (P6), 0.1 mL VLPs SARS-CoV-2 10 μg + adjuvant 2 (P7), 0.1 mL VLPs SARS-CoV-2 50 μg + adjuvant 1 (P8), and 0.1 mL VLPs SARS-CoV-2 50 μg + adjuvant 2 (P9). The data analysed by using ANOVA